MedTrace Logo

sdAb-based TRNT of Multiple Myeloma: a Feasibility Study

NCT03956615 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-12-01

Study results available
· View outcomes & findings →

Summary

This study aims to show that antiidiotypic sdAb are a new, sensitive, specific and non-invasive tool for imaging and therapeutic purposes and provides a rationale for their clinical evaluation as a personalized treatment option for MM patients expressing surface paraprotein.

Conditions

Interventions

OTHER

Blood sampling and bone marrow analysis

Bone marrow sample analysis. A blood sampling of maximally 10 ml by venous puncture (serum)

Sponsors & Collaborators

  • Stichting tegen Kanker

    collaborator OTHER

  • Universitair Ziekenhuis Brussel

    lead OTHER

Principal Investigators

  • Marleen Keyaerts, MD · Universitair Ziekenhuis Brussel

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-12
Primary Completion
2020-12-01
Completion
2020-12-01

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03956615 on ClinicalTrials.gov